CD274 and non-small cell lung carcinoma: The ATEZO-BRAIN study was a phase II trial investigating atezolizumab with carboplatin and pemetrexed in 40 non-squamous NSCLC patients with stable untreated BM either without neurological symptoms or managed with anticonvulsants or a maximum of 4 mg daily of dexamethasone, without considering PD-L1 expression [58].